Here's Why You Need To Watch FOMX Today...

(RTTNews) - Shares of Foamix Pharmaceuticals Ltd. (FOMX) have gained nearly 32% in the last 3 months, and phase II results to be reported today, on September 12, 2016, can impact the stock price this week.

The catalyst in focus is the phase II clinical trial of FMX103 for the treatment of papulopustular rosacea.

The phase II trial involved 233 patients who were enrolled in 18 sites throughout Germany. Patients were randomized to receive high dose FMX103 (3% minocycline foam), low dose FMX103 (1.5% minocycline foam) or vehicle foam over 12 weeks, followed up by a 4-week post-treatment evaluation. The primary endpoints are safety, tolerability and efficacy in the treatment of moderate-to-severe papulopustular rosacea.

Papulopustular rosacea is a chronic skin disorder characterized by facial redness and inflammatory lesions. It affects more than 16 million people in the U.S. alone.

Will the phase II clinical data of FMX103 bring cheers to investors?

Stay tuned for more updates...

FOMX closed Friday's trading at $8.79, up 0.46%.